Substance / Medication

Dihydroergocryptine

Overview

Active Ingredient
dihydroergocryptine
RxNorm CUI
3417

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Bioequivalence of a novel high-dose oral formulation of alpha-dihydroergocryptine.
de Mey Christian, Stamenova Paraskeva, Daskalov Marin et al. · Arzneimittelforschung · 2006
PMID: 16618013RCT
[Effect of alpha dihydroergocryptine in patients with fibrocystic breast disease].
Castillo Eugenio, Garibay Miguel, Mirabent Felio · Ginecol Obstet Mex · 2006
PMID: 17357577RCT
[Clinical comparision of alpha dihydroergocryptine against cabergoline in the treatment of the fibrocystic mastopathy].
Castillo-Huerta Eugenio, Garibay-Valencia Miguel, Mirabent-González Felio · Ginecol Obstet Mex · 2013
PMID: 23971383Observational
Plasma and urine pharmacokinetics of the dopamine agonist alpha-dihydroergocryptine in patients with hepatic dysfunction.
Althaus M, de Mey C, Ezan E et al. · Int J Clin Pharmacol Ther · 2001
PMID: 11270804Observational
Pleural fibrosis associated with dihydroergocryptine treatment.
Oechsner M, Groenke L, Mueller D · Acta Neurol Scand · 2000
PMID: 10770528Case Report
Determination of dihydroergocryptine in human plasma and urine samples using on-line sample extraction-column-switching reversed-phase liquid chromatography-mass spectrometry.
Friedrich Gerhard, Appel Kurt, Rose Thorsten et al. · J Chromatogr B Analyt Technol Biomed Life Sci · 2004
PMID: 15261806Other
Synergistic effect of alpha-dihydroergocryptine and L-dopa or dopamine on dopaminergic neurons in primary culture.
Gille G, Radad K, Reichmann H et al. · J Neural Transm (Vienna) · 2006
PMID: 16252065Preclinical
Alpha-dihydroergocryptine in the long-term therapy of Parkinson's disease.
Mailland Enrico, Magnani Paola, Ottillinger Bertram · Arzneimittelforschung · 2004
PMID: 15553103Trial
Single dose pharmacokinetics of alpha-dihydroergocryptine in patients with moderate to severe renal insufficiency.
de Mey Christian, Sułowicz Władyslaw, Stompór Tomasz et al. · Arzneimittelforschung · 2003
PMID: 14677372Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Dihydroergocryptine (substance)
SNOMED CT
412173004
UMLS CUI
C0012290
RxNorm CUI
3417

Clinical Data

This intervention maps to 3 entities in the Healos knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.